Gland Pharma Board Approves Grant of 16,790 Options under ESOP 2025
The ESOP Compensation Committee of the Board of Directors at Gland Pharma Ltd has approved the grant of Employee Stock Options (ESOP) as part of the Gland Pharma Employee Stock Option Scheme, 2025. The approval came during a meeting held on July 30, 2026.The grant pertains to the company's ongoing stock option initiatives and continues from an earlier intimation made on May 15, 2026. Under the approval, a total of 16,790 options were granted to three employees of the Company under the ESOP 2025 scheme.
The terms and conditions for these granted stock options are detailed below:
| Particulars | Details |
|---|---|
| Total Options Granted | 16,790 |
| Number of Employees Benefitting | 3 |
| Grant Price Range | 11,081 options at INR 1258.50 (50% of the closing price on NSE on July 30, 2026) and 5,709 options at INR 1/- (Face value). |
| Vesting Schedule | 34% of total granted options will vest upon completion of the first year from the date of vesting (July 30, 2027); 33% will vest upon completion of the second year (July 30, 2028); and the remaining 33% will vest on completion of the third year (July 30, 2029). |
| Exercise Period | Options must be exercised within a maximum period of two years from the date of vesting. |
The granted stock options are administered by the ESOP Compensation Committee of the Board of Directors and fall under the Gland Pharma Employee Stock Option Scheme, 2025.
GLAND Stock Price Movement
Shares of Gland Pharma Limited today slipped by 0.85% to close at ₹2517, seeing a trading volume of 745,911 shares. The stock, which was noted during the year, had previously reached an impressive 52-week high of ₹2586.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.